{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:28:43Z","timestamp":1791300523867,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Statins have a variety of myotoxic effects and can trigger the development of inflammatory myopathies or myasthenia gravis (MG) mediated by immunomodulatory properties. Autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) have been identified in patients with statin-associated myopathy. The purpose of the present study is to develop an enzyme-linked immunosorbent assay (ELISA) of anti-HMGCR antibodies and to elucidate the clinical significance of anti-HMGCR antibodies in Japanese patients with inflammatory myopathies or MG.<\/jats:p>\n                    <jats:p>We enrolled 75 patients with inflammatory myopathies, who were all negative for anti-signal recognition particle and anti-aminoacyl transfer RNA synthetase antibodies. They were referred to Keio University and National Center of Neurology and Psychiatry between October 2010 and September 2012. We also studied 251 patients with MG who were followed at the MG Clinic at Keio University Hospital. Anti-HMGCR antibodies were detected by ELISA. We investigated demographic, clinical, radiological, and histological findings associated with anti-HMGCR antibodies.<\/jats:p>\n                    <jats:p>\n                      We established the anti-HMGCR ELISA with the recombinant protein. Protein immunoprecipitation detected autoantigens corresponding to HMGCR. Immunohistochemistry using muscle biopsy specimens revealed regenerating muscle fibers clearly stained by polyclonal anti-HMGCR antibodies and patients\u2019 serum. Anti-HMGCR autoantibodies were specifically detected in 8 patients with necrotizing myopathy. The seropositivity rate in the necrotizing myopathy patients was significantly higher than those in the patients with other histological diagnoses of inflammatory myopathies (31% vs 2%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.001). Statins were administered in only 3 of the 8 anti-HMGCR-positive patients. Myopathy associated with anti-HMGCR antibodies showed mild limb weakness and favorable response to immunotherapy. All 8 patients exhibited increased signal intensities on short T1 inversion recovery of muscle MRI. Of the 251 patients with MG, 23 were administered statins at the onset of MG. One late-onset MG patient experienced MG worsening after 4-wk treatment with atorvastatin. However, anti-HMGCR antibodies were not detected in the 251 MG patients except for one early-onset MG patient with no history of statin therapy.\n                    <\/jats:p>\n                    <jats:p>Anti-HMGCR antibodies are a relevant clinical marker of necrotizing myopathy with or without statin exposure, but they are not associated with the onset or deterioration of MG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000000416","type":"journal-article","created":{"date-parts":[[2015,1,29]],"date-time":"2015-01-29T02:05:49Z","timestamp":1422497149000},"page":"e416","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":89,"title":["Statins and Myotoxic Effects Associated With Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies"],"prefix":"10.1097","volume":"94","author":[{"given":"Yurika","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ya","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kurashige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Ikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Asahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satsuki","family":"Mitsuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichizo","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20260903","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am Heart J"},{"key":"R2-10-20260903","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/mus.21072","article-title":"More evidence for the association between statins and myasthenia gravis","volume":"38","author":"de Sousa","year":"2008","journal-title":"Muscle Nerve"},{"key":"R3-10-20260903","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.23854","article-title":"Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies","volume":"48","author":"Mohassel","year":"2013","journal-title":"Muscle Nerve"},{"key":"R4-10-20260903","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R5-10-20260903","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R6-10-20260903","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar4468","article-title":"et al: Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies","volume":"16","author":"Drouot","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R7-10-20260903","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore"},{"key":"R9-10-20260903","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"R10-10-20260903","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(02)09846-X","article-title":"Statins, fibrates, and ocular myasthenia","volume":"360","author":"Parmar","year":"2002","journal-title":"Lancet"},{"key":"R11-10-20260903","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1212\/01.WNL.0000145708.03876.C3","article-title":"Statin-associated exacerbation of myasthenia gravis","volume":"63","author":"Cartwright","year":"2004","journal-title":"Neurology"},{"key":"R12-10-20260903","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/01.md.0000209337.59874.aa","article-title":"Statin-associated myasthenia gravis: report of 4 cases and review of the literature","volume":"85","author":"Purvin","year":"2006","journal-title":"Medicine (Baltimore"},{"key":"R13-10-20260903","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/mus.21074","article-title":"Statins may aggravate myasthenia gravis","volume":"38","author":"Oh","year":"2008","journal-title":"Muscle Nerve"},{"key":"R14-10-20260903","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1111\/j.1468-1331.2008.02234.x","article-title":"Ptosis, diplopia and statins: an association?","volume":"15","author":"Elsais","year":"2008","journal-title":"Eur J Neurol"},{"key":"R15-10-20260903","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jocn.2013.11.009","article-title":"Statins can induce myasthenia gravis","volume":"21","author":"Gale","year":"2014","journal-title":"J Clin Neurosci"},{"key":"R16-10-20260903","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jneuroim.2014.07.006","article-title":"Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies","volume":"274","author":"Suzuki","year":"2014","journal-title":"J Neuroimmunol"},{"key":"R17-10-20260903","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"R18-10-20260903","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2009.11.003","article-title":"Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London 2008","volume":"20","author":"Hilton-Jones","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"R19-10-20260903","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"R20-10-20260903","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2011.06.011","article-title":"Autoimmunity to endoplasmic reticulum chaperone GRP94 in myasthenia gravis","volume":"237","author":"Suzuki","year":"2011","journal-title":"J Neuroimmunol"},{"key":"R21-10-20260903","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jneuroim.2005.08.017","article-title":"Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis","volume":"170","author":"Suzuki","year":"2005","journal-title":"J Neuroimmunol"},{"key":"R22-10-20260903","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/archneurol.2011.1728","article-title":"Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome","volume":"69","author":"Suzuki","year":"2012","journal-title":"Arch Neurol"},{"key":"R23-10-20260903","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ncpneuro0988","article-title":"Is it safe to use statins in patients with myasthenia gravis?","volume":"5","author":"Gilhus","year":"2009","journal-title":"Nat Clin Pract Neurol"},{"key":"R24-10-20260903","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.humimm.2013.06.020","article-title":"Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis","volume":"74","author":"Klein","year":"2013","journal-title":"Hum Immunol"},{"key":"R25-10-20260903","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005792-201501040-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:00:22Z","timestamp":1788458422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201501040-00010"}},"subtitle":["An Observational Study in Japan"],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000000416","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}